Publications by authors named "D B Dahl"
Article Synopsis
- * The study introduces a 3D printed multipurpose prevention technology (MPT) intravaginal ring (IVR) designed to prevent HIV, HSV-2, and unintended pregnancy, utilizing advanced 3D printing techniques and biocompatible materials.
- * The IVRs demonstrated stable drug release and safety in macaque studies, maintaining effectiveness and tolerability over a 28-day period without causing any significant inflammatory responses.
Objective: To assess 30-day outcomes of da Vinci robotic-assisted (dV-RAS) versus laparoscopic/thoracoscopic (lap/VATS) or open oncologic surgery.
Summary Background Data: Complex procedures in deep/narrow spaces especially benefit from dV-RAS. Prior procedure-specific comparisons are not generalizable.
Monitoring surgical nociception using multisensor physiological models.
Proc Natl Acad Sci U S A
October 2024
Article Synopsis
- * Researchers collected a large dataset from 101 surgeries to analyze nociceptive stimuli and medication use, developing new models that can objectively measure surgical nociception more accurately than existing methods.
- * Their findings suggest that the new models aligned well with known physiological responses to pain, representing progress toward establishing reliable, objective markers for monitoring surgical nociception during operations.
Article Synopsis
- There is limited data on predicting outcomes of pyeloplasty in adult patients with ureteropelvic junction obstruction (UPJO), leading to challenges in defining success rates.
- To address biases in evaluating surgical success, researchers conducted unsupervised machine learning analyses on 216 pyeloplasty patients to identify key risk factors for poor outcomes.
- Two patient clusters were found: a "high-risk" group characterized by older age, higher BMI, and comorbidities such as hypertension and past surgeries, which experienced more severe postoperative complications.
Background: Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials.
Methods: We conducted a 52-week, phase 3, parallel-design, open-label, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin.